or poor-tolerated AFL Clinical history, other arrhythmias as atrial fibrillation (AF), data of echocardiography were collected. The patients were followed from 3 months up to 10 years.
Introduction:
Studies have documented the underuse of oral anticoagulant therapy (OAC) as stroke prophylaxis in older persons with history of atrial fibrillation (AF). Failure to prescribe OAC is often due to the perception by physicians of bleeding because of specific older people clinical factors.
We performed a prospective observational study in the University Hospital of Reims, whose aim was to evaluate the management of thromboembolic risk in older patients in everyday-life hospital practice and impact of frailty and dependence objective parameters.
Method: 150 AF patients over 75 years were consecutively included over a period of four months. Clinical and biological data, risk scores for bleeding (HASBLED) and thrombo-embolic events (CHADS and CHADSVASc) were computed. Several scores and parameters of assessment of autonomy and risk of falling were independently recorded: MMS (Mini-Mental Status), ADL (Activities of Daily Living) and IADL (Instrumental ADL).
Results: Mean age was 83±13 years (75 men). At discharge, 52.2% of patients were under OAC. Mean CHADS, CHADSVASc and HASBLED score were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1; all patients had a CHA DS VASc score ≥2 and 86% a CHADS ≥2. The HASBLED score was associated with non-prescription of anticoagulation (p=0.001), while none of the thrombo-embolic scores was significantly associated with prescription. Specific studied parameters are in table.
Conclusion:
In our study of everyday practice, there is an underuse of anticoagulation in the elderly compared to guidelines, mainly because the perception of the hemorrhagic risk prevails over the thrombo-embolic risk. Specific geriatric parameters could help to choose the appropriate therapy.
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Oral anticoagulation therapy in older patients with atrial fibrillation: an evaluation of daily practice with regard to guidelines and scores in a cohort of 142 patients Colette Rio (1), François Lesaffre (1), Pierre Nazeyrollas (1), Jean Luc Novella (2), Sophie Tassan-Mangina (1), Sarah Ledon (1), Damien Metz (1) (1) CHU Reims Robert Debré, cardiologie, Reims, France -(2) CHU Reims, gériatrie, Reims, France Introduction: Age is a major thrombo-embolic risk factor in atrial fibrillation (AF), but also a risk factor for bleeding under oral anticoagulation therapy (OAC). However, it appears that older patients are inadequately treated with OAC.
The objective of our study was to evaluate the use of OAC in elderly patients hospitalised in a cardiology department according to current guidelines.
Method:
Over a 4-month period, 142 patients over 75 years old with history of AF were included. Clinical and biological data were recorded, and risk scores for bleeding (HASBLED) and thrombo-embolic events (CHADS 2 and CHA 2 DS 2 VASc) were independently assessed after discharge. The differences between bleeding and thrombo-embolic risk were calculated for each patient. Patients with OAC at discharge and patients without OAC were compared.
Results:
Mean age was 83±13 years (75 men). Mean CHADS, CHADS-VASc and HASBLED scores were respectively 2,6±0,1, 4,6±0,1 and 2,3±0,1. According to CHADSVASc score and guidelines all of the patients were eligible for OAC. However 47.8% of patients were not under OAC. Those patients were older (84.6±0.6 vs. 81.8±0.5; p=0.001), predominantly female (66 vs. 35%; p=0.001) with a higher serum creatinine (127.3±7.3 vs. 106±6.3; p=0.03) and HASBLED score (2.7 vs. 2.16; p=0.001). OAC use was not associated with CHADS and CHADSVASc scores values.
Conclusion:
Our study in daily pratice confirms that OAC in older patients with AF are underused and that the bleeding risk may be over-rated and/or thrombo-embolic risk under-estimated. However, specific risk factors in older patients may not be included in currently used scores.
Patients over 75 years of age with and without atrial fibrillation: characteristics and differences in a hospital cohort of 357 patients
Colette Rio (1), François Lesaffre (1), Pierre Nazeyrollas (1) We performed a prospective observational study which aimed to describe all patients over 75 years hospitalized in a cardiology department. For each patient we collected cause of hospitalisation, medical and cardiovascular history. We compared patients with and without previous history of AF ("AF group" versus "sinus group").
Results: Among 1050 patients admitted during an inclusion period of 4 months, 357 patients were older than 75 years: 150 in the "AF group" and 207 in the "sinus group". AF was paroxysmal, persistent and permanent respectively in 21%, 30%, and 48% of cases.
Table -Main data
Conclusion: Patients over 75 years of age accounted for 34% of patients admitted in our cardiology department and 42% of them had a history of atrial fibrillation.
AF patients had more frequently valvular disease, thyroid dysfunction, which are comorbidities associated with AF but also more strokes, dementia and hospitalization for heart failure which may be consequences of AF.
Prevalence and significance of stroke among patients with paroxysmal supraventricular tachycardia
Béatrice Brembilla-Perrot (1), Julien Delobelle (1), Jean Marc Sellal (2), Pierre Yves Zinzius (1), Jérôme Schwartz (1), Mahesh Pauriah (2), Gabriel Cismaru (2), Joseph Rizk (1), Christian De Chillou (1), Daniel Beurrier (1), Pierre Louis (1), Olivier Selton (1), Arnaud Terrier De La Chaise (1) (1) CHU of Brabois, cardiologie, Vandoeuvre Les ancy, France -(2) Cardiologie, CHU de Brabois, Vandoeuvre Les ancy, France
The risk of atrial fibrillation (AF) in patients with paroxysmal supraventricular tachycardia (SVT) is well-known. AF is a cause of embolic event and a risk of stroke in patients with SVT can be expected. The purpose of the study was to assess the prevalence of unexplained stroke in patients presenting with SVT and to look for the risk factors.
Methods: Electrophysiological study (EPS) was performed in 1379 patients without anterograde conduction through accessory pathway (AP) for SVT. Clinical and electrophysiological data were collected.
Results: Stroke was noted in 38 patients (group I) (prevalence 2.8%). 1341 patients had no stroke (group II). 1) Clinical data: Group I was older than group II (62±13 vs 49±19 years) (p<0.0002). Associated heart disease (14/38, 37% vs 139/1341, 10%)(p<0.0001), AF history (4/38, 10.5%, 32/1341, 2%, p<0.002) were more frequent in group I than in group II. Male gender was similar in both groups. 2) Electrophysiological data: SVT mechanism was similar: AV re-entrant tachycardia in a concealed AP was noted in 4 group I patients (10.5%) and 247 group II patients (18%)(NS). Signs of atrial vulnerability were as frequent in both groups. 3) Follow-up (mean 3±3 years): Adverse events (AE) occurred in 102 patients: 3 group II patients presented a stroke; AF occurred in 8 group I patients (21%), 62 group II patients (5%)(p<0.0001); 3 group I patients (8%), 26 group II patients (2%) died from cardiovascular death (p<0.01). SVT ablation was performed in 65 of 102 patients (64%) with AE (AF or death), 790 of 1277 patients without AE (62%)(NS). Age (p=0.001), prior AF (p=0.001) were the 2 independent risk factors of stroke at multivariate analysis stroke. Adjusted on age, heart disease was not significantly associated with stroke.
Conclusions:
Unexplained stroke was a rare event in patients with paroxysmal SVT (2.8%). Old age, and AF history were the only independent significant factors associated with the history of stroke in these patients. They had a risk of severe adverse events during the follow-up as spontaneous AF (21%) or death (8%). SVT ablation did not reduce the risk of new stroke, spontaneous AF or death.
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Safety and effectiveness of catheter ablation of atrial fibrillation before 30 years of age Khaled Ramoul, Sebastien Knecht, Nicolas Derval, Frederic Sacher, Meleze Hocini, Pierre Jaïs, Jacques Clementy, Michel Haïssaguerre Hopital cardiologique Haut Leveque, Pessac, France Introduction: Catheter ablation has emerged as a realistic therapeutic option for symptomatic atrial fibrillation (AF). Young patients with AF are often more symptomatic and long-term taking medication is very demanding for their daily life. The aim of our study is to describe the safety and the longterm effectiveness of catheter ablation of AF in patients under 30 years of age.
Methods and results:
Twenty five consecutive patients < 30 years old (mean age: 26±3; 16-29) with paroxysmal (13 pts, 52%) or persistent AF (12 pts, 48%, AF duration 40±24 months) underwent catheter ablation of symptomatic atrial fibrillation refractory to at least one antiarrythmic drug (AAD), in our center. Only 3 patients had structural heart disease (hypertrophic cardiomyopathy). Patients were hospitalized and monitored at 3, 6 and 12 months, every 6 months thereafter and at the end of the follow up. Mean radio frequency duration was 51±29 min (39±14 for PAF and 65±40 for PsAF) for total procedure time of 176±91 min (128±55 for PAF and 224±100 for PsAF) and a fluoroscopic time of 52±33 min (38±20 for PAF and 62±36 for PsAF). In all procedures, no major complication occurred. After a mean follow up of 54 months ± 29; 21/25 (84%) patients remained arrhythmia-free (92% for PAF and 76% for PsAF) after a mean of 1.6 procedure per patient. 19 of the 21 arrhythmia free patients were also AAD free. Only 3 patients of these 21 patients were treated with warfarin.
Conclusion:
These finding suggest that catheter ablation of AF in patients under 30 years of age is safe, with good clinical long term outcome. Catheter ablation of AF can be first-line therapy in young people.
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Are QT intervals correlated to apnea-hypopnea index in obstructive sleep apnea?
Afef Ben Halima (1), Houcine Chammam (1), Manel Ben Halima (1), Sonia Maalej (2), Hend Keskes (1), Samira Chine (1), Sami Gargouri (1), Sonia Marrakchi (1), Faouzi Addad (1), Ikram Kammoun (1), Ikram Drira (2), Nadia Hammami (1), Salem Kachboura (1 
